Subscribe

Addex Therapeutics Ltd (ADXN.SW)

CHF0.04 +0.00 (+1.52%)
CH SIX Healthcare Biotechnology
Address Chemin des Mines, 9 1202
Geneva, CH
CEO Timothy Mark Dyer
Website addextherapeutics.com
IPO 2007-05-22
ISIN CH0029850754

Explore sections of this company profile

Also trades on London Stock Exchange · 0QNV.L (CHF) NASDAQ Capital Market · ADXN (USD) Other OTC · ADDXF (USD) Swiss Exchange · ADXN.SW (CHF)
Description

Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CHF0.04 +0.00 (+1.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
201.7K
Beta
1.97
Float Shares
122.04M
Free Float %
80.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.88% -2.54% -7.26% -4.17% -17.86% -13.21% -22.03% -61.02% -97.02% -98.02% -99.93%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Analyst Consensus (1 ratings, all time) Hold
Price Targets & DCF
Current price
0.04
DCF (Unlevered) 0.01 -78.6%
DCF (Levered) 0.01 -69.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 0% Bullish
Rating 2025-12 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 1 0
Strong Sell 0 -1
Quality scores
Altman Z-Score
-79.56
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -57.8% Q1'26: -89.2% (vs Q1'25)
  • ✗
    EPS growth Biotechnology: +29.7%
    -185.7% Q1'26: +33.3% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -1,318.9% Q1'26: -9,957.6% (vs Q1'25)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -1,627.2% Q1'26: -6,241.1% (vs Q1'25)
  • ✗
    ROIC Biotechnology: -16.1%
    -89.2% Q1'26: -78.3% (vs Q1'25)
  • ✗
    Share dilution Biotechnology: -3.4%
    +14.0% Q1'26: +74.1% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.01× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.98) × ERP
WACC = 99% × Ke + 1% × Kd (46.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.01 Current price: 0.04
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana.
Revenue
40.3K
est: 200.0K (-79.8%)
17.3K
est: 200.0K (-91.3%)
499.9K
est: 488.0K (+2.4%)
6.04M
est: 3.34M (+81.1%)
2.76M
est: 3.49M (-20.9%)
3.61M
est: 2.85M (+26.8%)
2.92M
est: 3.48M (-16.1%)
1.42M
est: 1.15M (+23.7%)
1.61M
est: 1.10M (+46.6%)
410.0K
est: 954.5K (-57.0%)
173.0K
est: 1.50M (-88.5%)
1.50M
1.50M – 1.50M
+0.0% YoY
7.00M
7.00M – 7.00M
+366.7% YoY
EBITDA
-4.18M
est: -200.0K (-1,989.2%)
-3.12M
est: -200.0K (-1,461.8%)
-3.27M
est: -488.0K (-569.1%)
-1.51M
est: -3.34M (+54.8%)
-14.32M
est: -3.49M (-309.9%)
-12.41M
est: -2.85M (-335.7%)
-14.94M
est: -3.48M (-329.8%)
-20.43M
est: -1.15M (-1,676.7%)
-10.26M
est: -1.10M (-832.4%)
-4.65M
est: -954.5K (-386.7%)
-2.82M
est: -1.50M (-87.7%)
-1.50M
-1.50M – -1.50M
+0.0% YoY
-7.00M
-7.00M – -7.00M
-366.7% YoY
EBIT
-4.20M
est: -200.0K (-2,002.1%)
-3.15M
est: -200.0K (-1,474.7%)
-3.28M
est: -488.0K (-572.2%)
-1.51M
est: -3.34M (+54.7%)
-14.65M
est: -3.49M (-319.5%)
-12.79M
est: -2.85M (-349.0%)
-15.29M
est: -3.48M (-339.8%)
-20.76M
est: -1.15M (-1,704.8%)
-10.53M
est: -1.10M (-857.7%)
-4.91M
est: -954.5K (-414.0%)
-2.82M
est: -1.50M (-87.7%)
-1.50M
-1.50M – -1.50M
+0.0% YoY
-7.00M
-7.00M – -7.00M
-366.7% YoY
Net Income
-4.20M
est: -35.40M (+88.1%)
-3.15M
est: -35.40M (+91.1%)
-3.28M
est: -33.44M (+90.2%)
-1.64M
est: -11.80M (+86.1%)
-14.78M
est: -41.14M (+64.1%)
-12.86M
est: -53.60M (+76.0%)
-15.41M
est: -42.62M (+63.8%)
-20.80M
est: -43.27M (+51.9%)
-10.56M
est: -13.77M (+23.3%)
7.06M
est: -7.29M (+196.8%)
-6.73M
est: -7.85M (+14.3%)
-4.49M
-4.49M – -4.49M
+42.9% YoY
-3.36M
-3.36M – -3.36M
+25.0% YoY
SGA
1.57M
est: 621.8K (+152.1%)
1.52M
est: 621.8K (+144.8%)
2.20M
est: 1.52M (+44.7%)
4.72M
est: 10.38M (-54.5%)
4.27M
est: 10.86M (-60.7%)
5.15M
est: 8.86M (-41.9%)
5.14M
est: 10.81M (-52.5%)
7.30M
est: 3.58M (+104.2%)
2.57M
est: 3.42M (-24.8%)
2.31M
est: 4.78M (-51.7%)
1.89M
est: 7.51M (-74.9%)
7.51M
7.51M – 7.51M
+0.0% YoY
35.05M
35.05M – 35.05M
+366.7% YoY
EPS
-0.39
est: -0.36 (-8.3%)
-0.28
est: -0.36 (+22.2%)
-0.25
est: -0.34 (+26.5%)
-0.07
est: -0.12 (+41.2%)
-0.56
est: -0.42 (-33.9%)
-0.48
est: -0.55 (+11.9%)
-0.45
est: -0.43 (-3.8%)
-0.46
est: -0.44 (-4.5%)
-0.14
est: -0.14 (+0.0%)
0.07
est: -0.07 (+210.6%)
-0.06
est: -0.07 (+14.3%)
-0.04
-0.04 – -0.04
+42.9% YoY
-0.03
-0.03 – -0.03
+25.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-28 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-27 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-26 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-22 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-21 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-20 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-19 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-18 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-15 C+ 2/5 3/5 1/5 1/5 4/5 1/5 3/5
2026-05-13 B- 2/5 3/5 1/5 1/5 4/5 1/5 4/5
2026-05-12 B- 2/5 3/5 1/5 1/5 4/5 1/5 4/5
2026-05-11 B- 2/5 3/5 1/5 1/5 4/5 1/5 4/5
2026-05-08 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-29 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-28 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-27 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-24 C+ 2/5 3/5 1/5 1/5 3/5 1/5 4/5
2026-04-23 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-22 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-21 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-20 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-17 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5
2026-04-16 C+ 2/5 3/5 1/5 1/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-2.22M
OE per share TTM
-0.02
Owner's Yield
-33.92%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
19.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 1 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares Core SPI(R) ETF (CH) CHSPI.SW 0.00% 4.4K 0.10%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-14.1K
Shares Outstanding
151.90M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Roger G. Mills Chief Medical Officer & Director 25.7K —
Lénaic Teyssédou Head of Finance — male
Mikhail Kalinichev Head of Translational Science — —
Timothy Mark Dyer Co-Founder, Chief Executive Officer & Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology